Abstract
18F-FDG PET/CT has been described as an accurate tool for initial diagnosis of pancreatic adenocarcinoma. It differentiates benign from malignant causes; detects local and, especially, distant spread of disease; and is a very good predictor of patient prognosis. Pancreatic neuroendocrine tumors are rare tumors that originate from the islet cells of the pancreas. Currently, 68Ga-DOTA-labeled somatostatin analogs are considered the best modality for detection of well-differentiated neuroendocrine tumors. 18F-FDG PET/CT has a role in patients with poorly differentiated tumors. Recent studies have demonstrated improved survival in patients with metastatic neuroendocrine tumors treated with radiolabeled somatostatin analogs.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 407-421 |
| Number of pages | 15 |
| Journal | PET Clinics |
| Volume | 12 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 1 2017 |
Fingerprint
Keywords
- Pancreatic adenocarcinoma
- Pancreatic cancer
- Pancreatic neuroendocrine tumor
- PET
- PET/CT
ASJC Scopus subject areas
- Radiation
- Radiology Nuclear Medicine and imaging
Cite this
PET–Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors. / Pinho, Daniella F.; Subramaniam, Rathan M.
In: PET Clinics, Vol. 12, No. 4, 01.10.2017, p. 407-421.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - PET–Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors
AU - Pinho, Daniella F.
AU - Subramaniam, Rathan M.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - 18F-FDG PET/CT has been described as an accurate tool for initial diagnosis of pancreatic adenocarcinoma. It differentiates benign from malignant causes; detects local and, especially, distant spread of disease; and is a very good predictor of patient prognosis. Pancreatic neuroendocrine tumors are rare tumors that originate from the islet cells of the pancreas. Currently, 68Ga-DOTA-labeled somatostatin analogs are considered the best modality for detection of well-differentiated neuroendocrine tumors. 18F-FDG PET/CT has a role in patients with poorly differentiated tumors. Recent studies have demonstrated improved survival in patients with metastatic neuroendocrine tumors treated with radiolabeled somatostatin analogs.
AB - 18F-FDG PET/CT has been described as an accurate tool for initial diagnosis of pancreatic adenocarcinoma. It differentiates benign from malignant causes; detects local and, especially, distant spread of disease; and is a very good predictor of patient prognosis. Pancreatic neuroendocrine tumors are rare tumors that originate from the islet cells of the pancreas. Currently, 68Ga-DOTA-labeled somatostatin analogs are considered the best modality for detection of well-differentiated neuroendocrine tumors. 18F-FDG PET/CT has a role in patients with poorly differentiated tumors. Recent studies have demonstrated improved survival in patients with metastatic neuroendocrine tumors treated with radiolabeled somatostatin analogs.
KW - Pancreatic adenocarcinoma
KW - Pancreatic cancer
KW - Pancreatic neuroendocrine tumor
KW - PET
KW - PET/CT
UR - http://www.scopus.com/inward/record.url?scp=85023625779&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85023625779&partnerID=8YFLogxK
U2 - 10.1016/j.cpet.2017.05.003
DO - 10.1016/j.cpet.2017.05.003
M3 - Review article
C2 - 28867112
AN - SCOPUS:85023625779
VL - 12
SP - 407
EP - 421
JO - PET Clinics
JF - PET Clinics
SN - 1556-8598
IS - 4
ER -